Alternative pharmacologic targets for the treatment of schizophrenia: Results from phase I and II trials

Current Opinion in Psychiatry

Volumn 26, Issue 2, 2013, Pages 158-165

  Miyamoto, Seiya ^a   Jarskog, Lars F ^b,c   Fleischhacker, W Wolfgang ^d  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c Raleigh Campus   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

add on treatment; clinical trial; cognition; negative symptoms; schizophrenia

Indexed keywords

1,2,3,4,8,9,10,10A OCTAHYDRO 7BH CYCLOPENTA[B][1,4]DIAZEPINO[6,7,1 HI]INDOLE; 1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; 3 2,4 DIMETHOXYBENZYLIDENE ANABASEINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; AZD 0328; BITOPERTIN; BL 1020; CHOLINERGIC RECEPTOR STIMULATING AGENT; CP 809; CP 809101; CP 810123; DEXTRO SERINE; EGLUMETAD; EVP 6124; MEM 3454; MINOCYCLINE; MK 0777; N (1 AZABICYCLO[3.2.1]OCT 3 YL)FURO[2,3 C]PYRIDINE 5 CARBOXAMIDE; NEUROLEPTIC AGENT; OLANZAPINE; OXYTOCIN; PH 399733; PLACEBO; POMAGLUMETAD METHIONIL; R 3487; R 3487MEM 3454; RECOMBINANT ERYTHROPOIETIN; SARCOSINE; SEROTONIN 2C AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; VABICASERIN;

ADD ON THERAPY; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; MENTAL PATIENT; NEGATIVE SYNDROME; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; SCHIZOPHRENIA;

EID: 84873414007     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32835d8296     Document Type: Review

References (80)

1. Miyamoto S, Merrill DB, Lieberman JA, et al. Antipsychotic drugs. In: Tasman A, Kay J, Lieberman JA, et al., editors. Psychiatry. 3rd ed. Chichester: John Wiley & Sons; 2008. pp. 2161-2201
2. Miyamoto S, Miyake N, Jarskog LF, et al. Pharmacological treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012; 17:1206-1227
3. Stone JM, Pilowsky LS. Novel targets for drugs in schizophrenia. CNS Neurol Disord Drug Targets 2007; 6:265-272 (Pubitemid 47232938)
4. Jensen NH, Cremers TI, Sotty F. Therapeutic potential of 5-HT2C receptor ligands. Sci World J 2010; 10:1870-1885
5. Shen HQJ, Zhao Y, Rosenzweig-Lipson S, et al. A 6-week randomized, double-blind, placebo-controlled, comparator referenced, multicenter trial of vabicaserin in subjects with acute exacerbation of schizophrenia. Poster presented at ACNP 50th Anniversary Meeting; 4-8 December 2011; Waikoloa Beach, Hawaii, USA
6. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: A review of basic science and clinical studies. J Clin Psychopharmacol 2003; 23:601-640 (Pubitemid 37443192)
7. Lewis DA, Hashimoto T, Volk DW. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 2005; 6:312-324 (Pubitemid 40469985)
8. Geffen Y, Nudelman A, Gil-Ad I, et al. BL-1020: A novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Eur Neuropsychopharmacol 2009; 19:1-13
9. Appel L, Geffen Y, Heurling K, et al. BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. Eur Neuropsychopharmacol 2009; 19:841-850
10. Anand R, Geffen Y, Vasile D, Dan I. An open-label tolerability study of BL- 1020 antipsychotic: A novel gamma aminobutyric acid ester of perphenazine. Clin Neuropharmacol 2010; 33:297-302
11. Buchanan RW, Keefe RS, Lieberman JA, et al. A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. Biol Psychiatry 2011; 69:442-449
12. Lewis DA, Cho RY, Carter CS, et al. Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am J Psychiatry 2008; 165:1585-1593
13. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148:1301-1308
14. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996; 3:241-253 (Pubitemid 26058365)
15. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51:199-214 (Pubitemid 24081509)
16. Kantrowitz J, Javitt DC. Glutamatergic transmission in schizophrenia: From basic research to clinical practice. Curr Opin Psychiatry 2012; 25:96-102
17. Betz H, Gomeza J, Armsen W, et al. Glycine transporters: Essential regulators of synaptic transmission. Biochem Soc Trans 2006; 34:55-58 (Pubitemid 43235533)
18. Lane HY, Chang YC, Liu YC, et al. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebocontrolled study. Arch Gen Psychiatry 2005; 62:1196-1204
19. Tsai G, Lane HY, Yang P, et al. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55:452-456
20. Lane HY, Lin CH, Huang YJ, et al. A randomized, double-blind, placebocontrolled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010; 13:451-460
21. Lane HY, Liu YC, Huang CL, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: A randomized, double-blind study. Biol Psychiatry 2008; 63:9-12
22. Umbricht D, Martin-Facklam M, Pizzagalli F, et al. Glycine transporter type 1 (GLYT1) inhibitor RG1678: Results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Schizophr Bull 2011; 37 (suppl 1):324
23. Szegedi A, Jansen TW, Karson C, et al. Adjunctive treatment with the selective glycine uptake inhibitor Org 25935 in persistent negative symptoms of schizophrenia: Results from the GIANT trial. Poster presented at ACNP 50th Anniversary Meeting; Waikoloa Beach, Hawaii, USA. 4-8 December 2011
24. Rowley M, Bristow LJ, Hutson PH. Current and novel approaches to the drug treatment of schizophrenia. J Med Chem 2001; 44:477-501 (Pubitemid 32156091)
25. Chavez-Noriega LE, Schaffhauser H, Campbell UC. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr Drug Targets CNS Neurol Disord 2002; 1:261-281
26. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281:1349- 1352 (Pubitemid 28406826)
27. Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 2007; 13:1102-1107 (Pubitemid 47517511)
28. Kinon BJ, Zhang L, Millen BA, et al. A multicenter, inpatient, phase 2, doubleblind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol 2011; 31:349- 355
29. Kinon B, Adams DH, Baygani S, et al., editors. A long-term, phase 2, safety study of LY2140023 monohydrate versus atypical antipsychotic standard of care in schizophrenia. 13th International Congress on Schizophrenia Research; 2011; Colorado Springs. 30. Lilly. Lilly stops phase III development of pomaglumetad methionil for the treatment of schizophrenia based on efficacy results. http://newsroom.lilly. com/releasedetail.cfm?releaseid=703018. Press release, 29 August 2012. [Accessed 25 September 2012]
30. Wallace TL, Ballard TM, Pouzet B, et al. Drug targets for cognitive enhancement in neuropsychiatric disorders. Pharmacol Biochem Behav 2011; 99:130-145
31. Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl) 2004; 174:54-64 (Pubitemid 38925091)
32. Hauser TA, Kucinski A, Jordan KG, et al. TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 2009; 78:803-812
33. Mazurov A, Hauser T, Miller CH. Selective alpha7 nicotinic acetylcholine receptor ligands. Curr Med Chem 2006; 13:1567-1584 (Pubitemid 43821705)
34. Rezvani AH, Kholdebarin E, Brucato FH, et al. Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33:269-275
35. Acker BA, Jacobsen EJ, Rogers BN, et al. Discovery of N-[(3R,5R)-1-azabicyclo[ 3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: In vitro and in vivo activity. Bioorg Med Chem Lett 2008; 18:3611-3615 (Pubitemid 351787553)
36. EnVivo Pharmaceuticals. EnVivo reports positive results of its EVP-6124 clinical bio-marker study in schizophrenia patients. http://www.envivopharma. com/news-item.php?id=35. Press release, 5 December 2011
37. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165:1040-1047
38. Hosford D, Dunbar G, Lieberman JA, Segreti A. The alpha7 neuronal nicotinic receptor (NNR) agonist TC-5619 had beneficial effects and was generally well tolerated in a phase 2 trial in cognitive dysfunction in schizophrenia (CDS). 13th International Congress on Schizophrenia Research; 2011; Colorado Springs, Colorado, USA
39. Shiina A, Shirayama Y, Niitsu T, et al. A randomised, double-blind, placebocontrolled trial of tropisetron in patients with schizophrenia. Ann Gen Psychiatry 2010; 9:27
40. Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull 2007; 33:1100-1119 (Pubitemid 47347917)
41. Arneric SP, Holladay M, Williams M. Neuronal nicotinic receptors: A perspective on two decades of drug discovery research. Biochem Pharmacol 2007; 74:1092-1101 (Pubitemid 47417924)
42. Biedermann F, Fleischhacker WW. Antipsychotics in the early stage of development. Curr Opin Psychiatry 2009; 22:326-330
43. Smith RC, Lindenmayer JP, Davis JM, et al. Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 2009; 110:149-155
44. Shim JC, Jung DU, Jung SS, et al. Adjunctive varenicline treatment with antipsychotic medications for cognitive impairments in people with schizophrenia: A randomized double-blind placebo-controlled trial. Neuropsychopharmacology 2012; 37:660-668
45. Hong LE, Thaker GK, McMahon RP, et al. Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 2011; 68:1195-1206
46. Kohen I, Kremen N. Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry 2007; 164:1269-1270 (Pubitemid 47292424)
47. Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry 2007; 164:1269
48. Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007; 370:319-328 (Pubitemid 47094993)
49. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007; 18:129-140 (Pubitemid 46412082)
50. Zamberletti E, Rubino T, Parolaro D. The endocannabinoid system and schizophrenia: Integration of evidence. Curr Pharm Des 2012; 18:4980- 4990
51. Cota D, Sandoval DA, Olivieri M, et al. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity (Silver Spring) 2009; 17:1641-1645
52. Kelly DL, Gorelick DA, Conley RR, et al. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: A randomized, double-blind, pilot study. J Clin Psychopharmacol 2011; 31:86-91
53. Boggs DL, Kelly DL, McMahon RP, et al. Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial. Schizophr Res 2012; 134:207-210
54. Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012; 2:e94
55. Hallak JE, Machado-de-Sousa JP, Crippa JA, et al. Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). Rev Bras Psiquiatr 2010; 32:56-61
56. Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:336-339 (Pubitemid 351178944)
57. Levkovitz Y, Levi U, Braw Y, Cohen H. Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 2007; 1154:154-162 (Pubitemid 46856336)
58. Zhang L, Shirayama Y, Iyo M, Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007; 32:2004-2010 (Pubitemid 47258509)
59. Plane JM, Shen Y, Pleasure DE, Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010; 67:1442-1448
60. Dean OM, Data-Franco J, Giorlando F, Berk M. Minocycline: Therapeutic potential in psychiatry. CNS Drugs 2012; 26:391-401
61. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in earlyphase schizophrenia. J Clin Psychiatry 2010; 71:138-149
62. Chaudhry IB, Hallak J, Husain N, et al. Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26:1185-1193
63. Uvnas-Moberg K. Oxytocin may mediate the benefits of positive social interaction and emotions. Psychoneuroendocrinology 1998; 23:819-835 (Pubitemid 29049295)
64. Carter CS, Grippo AJ, Pournajafi-Nazarloo H, et al. Oxytocin, vasopressin and sociality. Prog Brain Res 2008; 170:331-336 (Pubitemid 352010239)
65. Feifel D, Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berl) 1999; 141:93-98 (Pubitemid 29193300)
66. Lee PR, Brady DL, Shapiro RA, et al. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology 2005; 30:1883-1894 (Pubitemid 41486413)
67. Caldwell HK, Stephens SL, Young WS 3rd. Oxytocin as a natural antipsychotic: A study using oxytocin knockout mice. Mol Psychiatry 2009; 14:190- 196
68. Kosfeld M, Heinrichs M, Zak PJ, et al. Oxytocin increases trust in humans. Nature 2005; 435:673-676 (Pubitemid 40825511)
69. Domes G, Heinrichs M, Michel A, et al. Oxytocin improves 'mind-reading' in humans. Biol Psychiatry 2007; 61:731-733
70. Guastella AJ, Einfeld SL, Gray KM, et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010; 67:692-694
71. Rubin LH, Carter CS, Drogos L, et al. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr Res 2010; 124:13- 21
72. Feifel D, Macdonald K, Nguyen A, et al. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 2010; 68:678-680
73. Pedersen CA, Gibson CM, Rau SW, et al. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res 2011; 132:50-53
74. Averbeck BB, Bobin T, Evans S, Shergill SS. Emotion recognition and oxytocin in patients with schizophrenia. Psychol Med 2012; 42:259-266
75. Feifel D, Macdonald K, Cobb P, Minassian A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr Res 2012; 139:207-210
76. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: A candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 2004; 9:42-54 (Pubitemid 38175081)
77. Siren AL, Fasshauer T, Bartels C, Ehrenreich H. Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 2009; 6:108-127
78. Ehrenreich H, Hinze-Selch D, Stawicki S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007; 12:206-220 (Pubitemid 46160985)
79. Wustenberg T, Begemann M, Bartels C, et al. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry 2011; 16:26-36
80. Rogers DP, Goldsmith CA. Treatment of schizophrenia in the 21st Century: Beyond the neurotransmitter hypothesis. Expert Rev Neurother 2009; 9:47- 54.